<DOC>
	<DOCNO>NCT02754817</DOCNO>
	<brief_summary>This study conduct Europe . The aim study investigate effectiveness Xultophy® ( insulin degludec/liraglutide ) adult real-world population type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Effectiveness Xultophy® ( Insulin Degludec/Liraglutide ) Adult Real-world Population With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Signed informed consent obtain studyrelated activity ( studyrelated activity procedure relate extraction data accord protocol ) Male female patient least 18 year age time inform consent Diagnosis T2DM ( type 2 diabetes mellitus ) Xultophy® initiation prescribe least 6 month inclusion study ( i.e. , date sign informed consent ) . Patients may may continue Xultophy® study inclusion Minimum available data : . ) At time Xultophy® prescription : HbA1c value ( unavailable , recent HbA1c value within 6 month first Xultophy® prescription ) ; b . ) At 6 month plus/minus 45 day first Xultophy® prescription : HbA1c value Type 1 diabetes Previous participation study . Participation define provide informed consent Participation clinical trial within 6 month 12 month first Xultophy® prescription ( Participation noninterventional study exclusion criterion ) Mental incapacity , unwillingness inability provide inform consent , language barrier preclude adequate understanding cooperation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>